Annals of Emergency Medicine
Volume 36, Issue 3 , Pages 191-197, September 2000

Intravenous Magnesium as an Adjuvant in Acute Bronchospasm: A Meta-Analysis

Presented in poster format at the Society for Academic Emergency Medicine, Boston, MA, May 1999.

  • Harrison J. Alter, MS, MD

      Affiliations

    • Robert Wood Johnson Clinical Scholars Program
  • ,
  • Thomas D. Koepsell, MD, MPH

      Affiliations

    • Department of Epidemiology
  • ,
  • William M. Hilty, MD

      Affiliations

    • University of Washington, Seattle, WA; and the Department of Emergency Medicine, Saint Mary’s Hospital and Medical Center, Grand Junction, CO.

Received 12 October 1999; received in revised form 1 May 2000 and 3 May 2000; accepted 17 May 2000.

Abstract 

Study Objective: Although several trials have been published evaluating intravenous magnesium sulfate as treatment for acute bronchospasm, its effectiveness for this indication remains unclear, prompting this meta-analysis. Methods: All randomized controlled trials of adjuvant bolus intravenous magnesium sulfate for acute bronchospasm in the emergency department were eligible. Trials were identified using MEDLINE, EMBASE, bibliographies of selected articles, and review of abstracts of 4 scientific societies. Two reviewers abstracted data, one of whom was blinded to author and journal. Because studies used different spirometric outcome measures, effect size was calculated for each study by Hedges’ method. The analysis used a fixed-effects model. One-way sensitivity analyses were performed to assess the influence of study quality and to search for publication bias. Results: Abstracts from 210 articles were reviewed, yielding 40 trials, of which 9 were specific to bolus intravenous magnesium sulfate in the ED, in doses from 1.2 to 2 g, or an equivalent pediatric dose. Combined results across 9 studies including 859 patients showed a posttreatment effect size of 0.162 for patients treated with intravenous magnesium sulfate (95% confidence interval 0.028, 0.297; P =.02). In sensitivity analyses exploring the effects of study quality and publication bias, the summary effect ranged from 0.127 to 0.206. No serious adverse events were reported. Conclusion: Adjuvant bolus intravenous magnesium sulfate in acute bronchospasm appears statistically beneficial in improving spirometric airway function by 16% of a SD. Although the clinical significance of this is uncertain, given the safety of intravenous magnesium sulfate therapy and its relatively low cost, it should be considered, absent contraindications, in patients with moderate to severe acute bronchospasm. [Alter HJ, Koepsell TD, Hilty WM. Intravenous magnesium as an adjuvant in acute bronchospasm: a meta-analysis. Ann Emerg Med. September 2000;36:191-197.]

 

 Address for reprints: Harrison J. Alter, MS, MD, Division of Emergency Medicine, University of Washington, Box 356123, Seattle, WA 98195-6123; 206-598-3345, fax 206-598-4569; E-mail halter@u.washington.edu .

PII: S0196-0644(00)27984-5

doi:10.1067/mem.2000.109170

Refers to article:

  • Intravenous Magnesium Sulfate Treatment for Acute Asthma in the Emergency Department: A Systematic Review of the Literature

    Brian H. Rowe, Jennifer A. Bretzlaff, Chris Bourdon, Gary W. Bota, Carlos A. Camargo
    Annals of Emergency Medicine September 2000 (Vol. 36, Issue 3, Pages 181-190)

  • Dueling Meta-Analyses

    Robert L. Wears
    Annals of Emergency Medicine September 2000 (Vol. 36, Issue 3, Pages 233-236)

Annals of Emergency Medicine
Volume 36, Issue 3 , Pages 191-197, September 2000